{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:39:53Z","timestamp":1792823993557,"version":"4.5.0"},"reference-count":285,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,2]],"date-time":"2027-10-02T00:00:00Z","timestamp":1822435200000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["CA264734"],"award-info":[{"award-number":["CA264734"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["5T32CA196561"],"award-info":[{"award-number":["5T32CA196561"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.canlet.2026.218856","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:48:04Z","timestamp":1790264884000},"page":"218856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting extracellular matrix mechanobiology to suppress solid tumor progression"],"prefix":"10.1016","volume":"661","author":[{"given":"Keefer","family":"Boone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghu Vamsi","family":"Kondapaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Libring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6959-3914","authenticated-orcid":false,"given":"Cynthia A.","family":"Reinhart-King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218856_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41568-020-00329-7","article-title":"The matrix in cancer","volume":"21","author":"Cox","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","article-title":"Matrix crosslinking forces tumor progression by enhancing integrin signaling","volume":"139","author":"Levental","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218856_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1741-7015-4-38","article-title":"Collagen reorganization at the tumor-stromal interface facilitates local invasion","volume":"4","author":"Provenzano","year":"2006","journal-title":"BMC Med."},{"key":"10.1016\/j.canlet.2026.218856_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-022-01252-0","article-title":"Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10137","article-title":"Role of YAP\/TAZ in mechanotransduction","volume":"474","author":"Dupont","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218856_bib6","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s43018-024-00775-4","article-title":"Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment","volume":"5","author":"Tharp","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ccr.2005.08.010","article-title":"Tensional homeostasis and the malignant phenotype","volume":"8","author":"Paszek","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218856_bib8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/ncb2756","article-title":"Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts","volume":"15","author":"Calvo","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib10","doi-asserted-by":"crossref","first-page":"15101","DOI":"10.1073\/pnas.1213353109","article-title":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","volume":"109","author":"Stylianopoulos","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2026.218856_bib11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218856_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccr.2008.11.012","article-title":"Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche","volume":"15","author":"Erler","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218856_bib13","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","article-title":"The interplay between extracellular matrix remodeling and cancer therapeutics","volume":"14","author":"Prakash","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218856_bib14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12951-025-03815-y","article-title":"Collagenase-mediated extracellular matrix targeting for enhanced drug penetration and therapeutic efficacy in nanoscale delivery systems for cancer therapy","volume":"23","author":"Gong","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.canlet.2026.218856_bib15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/427695a","article-title":"Cancer cells compress intratumour vessels","volume":"427","author":"Padera","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218856_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-026-03152-x","article-title":"Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors","author":"Lu","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218856_bib17","doi-asserted-by":"crossref","first-page":"8782","DOI":"10.1158\/1078-0432.CCR-05-1664","article-title":"The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors","volume":"11","author":"Primeau","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1172\/JCI45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218856_bib19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the Stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218856_bib20","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2026.218856_bib21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","article-title":"Trends in clinical success rates and therapeutic focus","volume":"18","author":"Dowden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218856_bib22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00280-013-2176-z","article-title":"Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues","volume":"72","author":"Patel","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218856_bib23","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218856_bib24","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","article-title":"Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumors","volume":"12","author":"Grout","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218856_bib25","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1158\/0008-5472.CAN-23-2352","article-title":"Multiplexed imaging mass cytometry analysis characterizes the vascular niche in pancreatic cancer","volume":"84","author":"Sussman","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaz0868","article-title":"Physical traits of cancer","volume":"370","author":"Nia","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218856_bib27","first-page":"18632","volume":"110","author":"Stylianopoulos","year":"2013"},{"key":"10.1016\/j.canlet.2026.218856_bib28","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218856_bib29","doi-asserted-by":"crossref","first-page":"15101","DOI":"10.1073\/pnas.1213353109","article-title":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","volume":"109","author":"Stylianopoulos","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2026.218856_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40364-025-00757-3","article-title":"Extracellular matrix: unlocking new avenues in cancer treatment","volume":"13","author":"Lee","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.canlet.2026.218856_bib31","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.ajpath.2010.11.076","article-title":"Aligned collagen is a prognostic signature for survival in human breast carcinoma","volume":"178","author":"Conklin","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2026.218856_bib32","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1158\/1078-0432.CCR-13-2972","article-title":"Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer","volume":"20","author":"Hartmann","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.hlife.2024.01.003","article-title":"Discoidin domain receptor 1 as a potent therapeutic target in solid tumors","volume":"2","author":"Bibi","year":"2024","journal-title":"Hlife"},{"key":"10.1016\/j.canlet.2026.218856_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006720","article-title":"A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer","volume":"11","author":"Liu","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib35","doi-asserted-by":"crossref","first-page":"AB010","DOI":"10.21037\/med-25-ab010","article-title":"AB010. a phase 1 trial of PRTH-101, a monoclonal antibody targeting discoidin domain receptor 1 (DDR1), alone or in combination with pembrolizumab, for the treatment of thymic malignancies","volume":"9","author":"Meric-Bernstam","year":"2025","journal-title":"Mediastinum"},{"key":"10.1016\/j.canlet.2026.218856_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.matbio.2023.12.003","article-title":"Novel insights into the role of discoidin domain receptor 2 (DDR2) in cancer progression: a new avenue of therapeutic intervention","volume":"125","author":"Trono","year":"2024","journal-title":"Matrix Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib37","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1084\/jem.20052554","article-title":"Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1","volume":"203","author":"Lebbink","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib38","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1038\/s41467-020-18298-8","article-title":"Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218856_bib39","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1158\/1535-7163.MCT-23-0866","article-title":"Antitumor activity of a novel LAIR1 antagonist in combination with anti-PD1 to treat collagen-rich solid tumors","volume":"23","author":"Rodriguez","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2026.218856_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12195-015-0417-4","article-title":"Fibronectin mechanobiology regulates tumorigenesis","volume":"9","author":"Wang","year":"2016","journal-title":"Cell. Mol. Bioeng."},{"key":"10.1016\/j.canlet.2026.218856_bib41","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-22-0099","article-title":"Anti-extra domain B splice variant of fibronectin antibody\u2013drug conjugate eliminates tumors with enhanced efficacy when combined with checkpoint blockade","volume":"21","author":"Hooper","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2026.218856_bib42","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3892\/mmr.2025.13525","article-title":"Exploring the mechanism of fibronectin extra domain B in the tumor microenvironment and implications for targeted immunotherapy and diagnostics","volume":"31","author":"Zhou","year":"2025","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2026.218856_bib43","doi-asserted-by":"crossref","first-page":"8314","DOI":"10.1073\/pnas.1505421112","article-title":"Tissue stiffness regulates serine\/arginine-rich protein-mediated splicing of the extra domain B-fibronectin isoform in tumors","volume":"112","author":"Bordeleau","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2026.218856_bib44","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1039\/C6TB02008A","article-title":"Targeting fibronectin for cancer imaging and therapy","volume":"5","author":"Han","year":"2017","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.canlet.2026.218856_bib45","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.18632\/oncotarget.27726","article-title":"A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo","volume":"11","author":"Ongaro","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218856_bib46","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.ejca.2010.07.033","article-title":"The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma","volume":"46","author":"Johannsen","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810020","article-title":"An attenuated targeted-TNF localizes to tumors in vivo and regains activity at the site of disease","volume":"22","author":"Dakhel","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218856_bib48","article-title":"Neoadjuvant intralesional Daromun (L19IL2\/L19TNF) in resectable locally advanced melanoma: an update on the efficacy and safety results of the PIVOTAL phase III trial","volume":"0","author":"Hauschild","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib49","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1245\/s10434-022-11447-x","article-title":"Efficacy of neoadjuvant intratumoral Darleukin\/Fibromun (L19IL2+ L19TNF) in patients with clinical stage IIIB\/C melanoma (Neo-DREAM)","volume":"29","author":"Saif","year":"2022","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jbiotec.2018.12.004","article-title":"A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors","volume":"291","author":"Ongaro","year":"2019","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218856_bib51","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ijc.20952","article-title":"Engineered vascular-targeting antibody-interferon-\u03b3 fusion protein for cancer therapy","volume":"116","author":"Ebbinghaus","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib52","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/imr.12391","article-title":"Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site","volume":"270","author":"Kiefer","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2026.218856_bib56","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00262-019-02383-z","article-title":"A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients","volume":"68","author":"Weide","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218856_bib57","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2326-6066.CIR-13-0206","article-title":"Intralesional treatment of stage III metastatic melanoma patients with L19\u2013IL2 results in sustained clinical and systemic immunologic responses","volume":"2","author":"Weide","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218856_bib58","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ijrobp.2020.11.053","article-title":"Toxicity of L19-Interleukin 2 combined with stereotactic body radiation therapy: a phase 1 study","volume":"109","author":"Van Limbergen","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2026.218856_bib59","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00262-015-1704-6","article-title":"Intralesional administration of L19-IL2\/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study","volume":"64","author":"Danielli","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218856_bib60","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.annonc.2025.06.014","article-title":"Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma","volume":"36","author":"K\u00e4hler","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib61","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1111\/jdv.20163","article-title":"Intratumoral administration of daromun in non-melanoma skin cancer: preliminary results from a phase 2 non-randomized controlled trial","volume":"39","author":"Flatz","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.canlet.2026.218856_bib62","article-title":"Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell\u2013dependent regression of glioblastoma","volume":"15","author":"Look","year":"2026","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib63","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf193.030","article-title":"KS04.7.A L19TNF in combination with temozolomide-based chemoradiation for patients with newly diagnosed glioblastoma SHOWS promising safety and overall survival signals in a phase I study","volume":"27","author":"Weiss","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb2311","article-title":"Immunocytokines are a promising immunotherapeutic approach against glioblastoma","volume":"12","author":"Weiss","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejca.2021.03.038","article-title":"Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas","volume":"150","author":"Schliemann","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jconrel.2023.06.008","article-title":"Fibronectin-targeted FUD and PEGylated FUD peptides for fibrotic diseases","volume":"360","author":"Lee","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2026.218856_bib54","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jconrel.2022.08.028","article-title":"Multimodal imaging demonstrates enhanced tumor exposure of PEGylated FUD peptide in breast cancer","volume":"350","author":"Lee","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2026.218856_bib55","article-title":"Inhibiting fibronectin assembly in the breast tumor microenvironment increases cell death and improves response to doxorubicin","author":"Gari","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.canlet.2026.218856_bib66","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1477-3163-5-2","article-title":"Expression of hyaluronan in human tumor progression","volume":"5","author":"Boregowda","year":"2006","journal-title":"J. Carcinog."},{"key":"10.1016\/j.canlet.2026.218856_bib67","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer","volume":"62","author":"Jacobetz","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2026.218856_bib68","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1535-7163.MCT-14-0580","article-title":"Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy","volume":"14","author":"Singha","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2026.218856_bib69","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1158\/0008-5472.CAN-18-3060","article-title":"Remodeling the tumor microenvironment sensitizes breast tumors to anti-programmed death-ligand 1 immunotherapy","volume":"79","author":"Clift","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib70","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1535-7163.MCT-10-0470","article-title":"Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models","volume":"9","author":"Thompson","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2026.218856_bib71","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer","volume":"62","author":"Jacobetz","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2026.218856_bib72","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0925-4439(00)00051-X","article-title":"Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition","volume":"1502","author":"Theocharis","year":"2000","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.canlet.2026.218856_bib73","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","article-title":"Halo 202: randomized phase II study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma","volume":"36","author":"Hingorani","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib74","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib75","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.17140\/poj-3-e010","article-title":"Why HALO 301 failed and implications for treatment of pancreatic cancer","volume":"3","author":"Hakim","year":"2019","journal-title":"Pancreas"},{"key":"10.1016\/j.canlet.2026.218856_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107958","article-title":"Hyaluronic acid and its role in pancreatic cancer: mechanisms of tumor progression, drug resistance, and therapeutic targeting","author":"Cai","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2026.218856_bib77","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.drudis.2020.07.003","article-title":"Advanced glycation end products in diabetes, cancer and phytochemical therapy","volume":"25","author":"Dariya","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.canlet.2026.218856_bib78","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.2174\/1381612825666190130145549","article-title":"Role of advanced glycation end products in carcinogenesis and their therapeutic implications","volume":"24","author":"Schr\u00f6ter","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.canlet.2026.218856_bib79","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20220395","article-title":"The RAGE\/multiligand axis: a new actor in tumor biology","volume":"42","author":"Rojas","year":"2022","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.canlet.2026.218856_bib80","doi-asserted-by":"crossref","first-page":"149","DOI":"10.14283\/jpad.2018.18","article-title":"Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild alzheimer's disease","volume":"5","author":"Burstein","year":"2018","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.canlet.2026.218856_bib81","article-title":"The RAGE inhibitor TTP488 (Azeliragon) demonstrates anti-tumor activity and enhances the efficacy of radiation therapy in pancreatic cancer cell lines","volume":"17","author":"Alka","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218856_bib82","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41523-023-00564-9","article-title":"RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer","volume":"9","author":"Magna","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib83","article-title":"Diabetic hyperglycemia promotes primary tumor progression through glycation-induced tumor extracellular matrix stiffening","volume":"8","author":"Wang","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218856_bib84","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1039\/D2SM00004K","article-title":"AGE-Breaker ALT711 reverses glycation-mediated cancer cell migration","volume":"18","author":"Rowe","year":"2022","journal-title":"Soft Matter"},{"key":"10.1016\/j.canlet.2026.218856_bib85","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.abb.2003.08.013","article-title":"Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts","volume":"419","author":"Thornalley","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.canlet.2026.218856_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2025.151527","article-title":"The role of the LOX family in cancer","volume":"105","author":"Boaru","year":"2026","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib87","doi-asserted-by":"crossref","DOI":"10.3402\/arb.v1.25247","article-title":"Matrix stiffening in the formation of blood vessels","volume":"1","author":"LaValley","year":"2014","journal-title":"Adv. Regenerat. Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib88","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1073\/pnas.1613855114","article-title":"Matrix stiffening promotes a tumor vasculature phenotype","volume":"114","author":"Bordeleau","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2026.218856_bib89","first-page":"1326","article-title":"A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer, Nat","volume":"4","author":"Chitty","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib90","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.3324\/haematol.2024.287231","article-title":"A phase I\/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis","volume":"110","author":"Vachhani","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2026.218856_bib91","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000970996.87048.d4","article-title":"P1024: MYLOX-1: a phase Ii study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of oral LOXL2 inhibitor GB2064 (with focus on bone marrow collagen) in patients with MYELOFIBROSIS","volume":"7","author":"Harrison","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.canlet.2026.218856_bib92","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-025-02192-0","article-title":"The molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer","volume":"10","author":"Guo","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.canlet.2026.218856_bib93","article-title":"A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer","author":"Piperigkou","year":"2025","journal-title":"FEBS J. n\/a"},{"key":"10.1016\/j.canlet.2026.218856_bib94","article-title":"Insights into the role of matrix metalloproteinases in cancer and its various therapeutic aspects: a review","volume":"9\u20132022","author":"Mustafa","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.canlet.2026.218856_bib95","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1535-7163.MCT-17-0646","article-title":"Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes","volume":"17","author":"Winer","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2026.218856_bib96","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1200\/JCO.20.02755","article-title":"Phase III study to evaluate efficacy and safety of andecaliximab with mFOLFOX6 as first-line treatment in patients with advanced gastric or GEJ adenocarcinoma (GAMMA-1)","volume":"39","author":"Shah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib97","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003580","article-title":"Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival","volume":"9","author":"Shah","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib98","article-title":"Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: interim clinical experience demonstrating feasibility and safety","volume":"6","author":"Barish","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib99","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1039\/D3BM02123H","article-title":"Enhancing the tumor penetration of multiarm polymers by collagenase modification","volume":"12","author":"Yu","year":"2024","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.canlet.2026.218856_bib100","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/10717544.2018.1474971","article-title":"Localized co-delivery of collagenase and trastuzumab by thermosensitive hydrogels for enhanced antitumor efficacy in human breast xenograft","volume":"25","author":"Pan","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.canlet.2026.218856_bib101","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2019.01.017","article-title":"Heparanase in health and disease: the neglected housekeeper of the cell?","volume":"283","author":"Shu","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.canlet.2026.218856_bib102","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12967-020-02624-1","article-title":"Heparanase and the hallmarks of cancer","volume":"18","author":"Jayatilleke","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib103","article-title":"Heparanase: a challenging cancer drug target","volume":"9\u20132019","author":"Coombe","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib104","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41416-018-0006-0","article-title":"A phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours","volume":"118","author":"Dredge","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib105","doi-asserted-by":"crossref","DOI":"10.1002\/chem.202104222","article-title":"Structural insights into pixatimod (PG545) inhibition of heparanase, a key enzyme in cancer and viral infections","volume":"28","author":"Chhabra","year":"2022","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.canlet.2026.218856_bib106","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006136","article-title":"Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors","volume":"11","author":"Lemech","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib107","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.182865","article-title":"Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy","volume":"103","author":"Galli","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2026.218856_bib108","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.3390\/molecules23112915","article-title":"Heparan sulfate mimetics in cancer therapy: the challenge to define structural determinants and the relevance of targets for optimal activity","volume":"23","author":"Lanzi","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.canlet.2026.218856_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/biom15071034","article-title":"Heparin, heparin-like molecules, and heparin mimetics in breast cancer: a concise review","volume":"15","author":"Gatica Portillo","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.canlet.2026.218856_bib110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.canlet.2026.218856_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057474","article-title":"TGF-\u03b2-elicited induction of tissue inhibitor of metalloproteinases (TIMP)-3 expression in fibroblasts involves complex interplay between Smad3, p38\u03b1, and ERK1\/2","volume":"8","author":"Leivonen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218856_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2024.102624","article-title":"Targeting cancer-associated fibroblasts with pirfenidone: a novel approach for cancer therapy","volume":"91","author":"Rastegar-Pouyani","year":"2024","journal-title":"Tissue Cell"},{"key":"10.1016\/j.canlet.2026.218856_bib113","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.15534","article-title":"Pirfenidone normalizes the tumor microenvironment to improve chemotherapy","volume":"8","author":"Polydorou","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218856_bib146","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.TPS244","article-title":"Jaguar (JACCRO PM-01): a prospective study to evaluate the clinical utility of serial comprehensive genomic profiling testing using circulating tumor DNA in patients with metastatic colorectal cancer","volume":"44","author":"Sunakawa","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib147","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1038\/s41467-024-51442-2","article-title":"The TGF\u03b2 type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed\/refractory multiple myeloma: a phase 1b trial","volume":"15","author":"Malek","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218856_bib148","article-title":"618P Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer","volume":"34","author":"Kim","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib116","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/s12885-023-11153-1","article-title":"A phase Ib\/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer","volume":"23","author":"Nadal","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib149","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002068","article-title":"Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","volume":"9","author":"Melisi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007353","article-title":"Phase I\/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-\u03b2 monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors","volume":"11","author":"Bauer","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib151","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/s41591-025-04157-w","article-title":"Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial","volume":"32","author":"Yap","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib152","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","article-title":"Bintrafusp Alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1\u2013High advanced NSCLC: a randomized, open-label, phase 3 trial","volume":"18","author":"Cho","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib120","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/HEP.0000000000000965","article-title":"Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: a randomized phase 2\/3 trial","volume":"81","author":"Oh","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2026.218856_bib121","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12916-022-02605-9","article-title":"Bifunctional anti-PD-L1\/TGF-\u03b2RII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial","volume":"20","author":"Liu","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.canlet.2026.218856_bib153","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-22-0346","article-title":"SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, for recurrent or metastatic cervical cancer: a clinical expansion cohort of a phase I study","volume":"28","author":"Feng","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib123","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41392-024-02052-3","article-title":"Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.canlet.2026.218856_bib122","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41392-025-02530-2","article-title":"A phase 1b\/2 study of first-line anti-PD-L1\/TGF-\u03b2RII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma","volume":"10","author":"Xue","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.canlet.2026.218856_bib126","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ccell.2024.05.024","article-title":"Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: a proof-of-concept, phase 2 trial","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218856_bib125","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.2025.43.4_suppl.410","article-title":"Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1\/TGF-\u03b2RII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): a phase II trial","volume":"43","author":"Liu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2302","article-title":"LBA60 phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric\/gastroesophageal junction adenocarcinoma (G\/GEJA)","volume":"35","author":"Peng","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib128","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-25-0100","article-title":"Phase I clinical trial of the bifunctional EGFR\/TGF-\u03b2 fusion protein ficerafusp Alfa (BCA101) alone and in combination with pembrolizumab for advanced solid tumors","volume":"31","author":"Hernando-Calvo","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib154","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000668","article-title":"Gemcitabine\/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer","volume":"5","author":"Picozzi","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.canlet.2026.218856_bib140","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2025.43.4_suppl.675","article-title":"LAPIS: randomized phase 3 trial of chemotherapy (CTX) with and without pamrevlumab (PAM) for locally advanced pancreatic cancer (LAPC)","volume":"43","author":"Picozzi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib145","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1078-0432.CCR-22-1630","article-title":"Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, tregs, and FOXP3+ cancer cells in locally advanced pancreatic cancer","volume":"29","author":"Boucher","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib155","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1200\/JCO.2026.44.16_suppl.4212","volume":"44","author":"Pathak","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib156","article-title":"P856 AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients","volume":"8","author":"Yap","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib157","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13736","article-title":"Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGF\u03b2) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors","volume":"17","author":"Robbrecht","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.canlet.2026.218856_bib158","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218856_bib159","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26218","article-title":"Immunological effects of the TGF\u03b2-blocking antibody GC1008 in malignant pleural mesothelioma patients","volume":"2","author":"Stevenson","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218856_bib160","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-17-3322","article-title":"Focal irradiation and systemic TGF\u03b2 blockade in metastatic breast cancer","volume":"24","author":"Formenti","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib161","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.ejca.2005.12.027","article-title":"Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours","volume":"42","author":"de Jonge","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib162","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/QAI.0b013e3181fc0141","article-title":"Phase II AIDS malignancy consortium trial of topical halofuginone in AIDS-related kaposi sarcoma","volume":"56","author":"Koon","year":"2011","journal-title":"JAIDS J. Acq. Immune Defic. Syndr."},{"key":"10.1016\/j.canlet.2026.218856_bib114","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1038\/s41467-024-51442-2","article-title":"The TGF\u03b2 type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed\/refractory multiple myeloma: a phase 1b trial","volume":"15","author":"Malek","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218856_bib115","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.canlet.2026.218856_bib117","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1426519","article-title":"M7824, a novel bifunctional anti-PD-L1\/TGF\u03b2 trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine","volume":"7","author":"Knudson","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218856_bib118","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008480","article-title":"Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with advanced non-small cell lung cancer","volume":"12","author":"Rajan","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib119","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","article-title":"Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1\u2013high advanced NSCLC: a randomized, open-label, phase 3 trial","volume":"18","author":"Cho","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib127","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/0008-5472.CAN-21-4425","article-title":"BCA101 is a tumor-targeted bifunctional fusion antibody that simultaneously inhibits EGFR and TGF\u03b2 signaling to durably suppress tumor growth","volume":"83","author":"Boreddy","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib129","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1200\/JCO.2023.41.16_suppl.6005","article-title":"Dose expansion results of the bifunctional EGFR\/TGF\u03b2 inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma","volume":"41","author":"Hanna","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib130","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/CIRCRESAHA.119.315999","article-title":"Glutamyl-Prolyl-tRNA synthetase regulates proline-rich pro-fibrotic protein synthesis during cardiac fibrosis","volume":"127","author":"Wu","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.canlet.2026.218856_bib131","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.0022-202x.2001.01690.x","article-title":"Halofuginone, an inhibitor of Type-I collagen synthesis and skin sclerosis, blocks Transforming-Growth-Factor-\u03b2-Mediated Smad3 activation in fibroblasts","volume":"118","author":"McGaha","year":"2002","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.canlet.2026.218856_bib132","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/10985549.2023.2205344","article-title":"EPRS1 controls the TGF-\u03b2 signaling pathway via interaction with T\u03b2RI in hepatic stellate cell","volume":"43","author":"Yoon","year":"2023","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib133","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.freeradbiomed.2022.05.017","article-title":"Halofuginone micelle nanoparticles eradicate Nrf2-activated lung adenocarcinoma without systemic toxicity","volume":"187","author":"Panda","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121855","article-title":"Microvesicle-inspired oxygen-delivering nanosystem potentiates radiotherapy-mediated modulation of tumor stroma and antitumor immunity","volume":"290","author":"Gong","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2026.218856_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.100981","article-title":"Dual-targeted halofuginone hydrobromide nanocomplexes for promotion of macrophage repolarization and apoptosis of rheumatoid arthritis fibroblast-like synoviocytes in adjuvant-induced arthritis in rats","volume":"14","author":"Zhu","year":"2024","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.canlet.2026.218856_bib136","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-023-00787-w","article-title":"Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma","volume":"13","author":"Kurata","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2026.218856_bib137","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216940","article-title":"Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl\u2010tRNA synthetase 1","volume":"15","author":"Yoon","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186587","article-title":"Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy","volume":"12","author":"Shibata","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218856_bib139","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s10555-025-10248-4","article-title":"Ctgf (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting","volume":"44","author":"Ghosh","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2026.218856_bib141","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/cells9040952","article-title":"CCN-based therapeutic peptides modify pancreatic ductal adenocarcinoma microenvironment and decrease tumor growth in combination with chemotherapy","volume":"9","author":"Resovi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218856_bib142","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12935-023-03080-9","article-title":"The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies","volume":"23","author":"Hassani","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.canlet.2026.218856_bib143","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Diop-Frimpong","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2026.218856_bib144","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1073\/pnas.1818357116","article-title":"Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma","volume":"116","author":"Zhao","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2026.218856_bib163","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.canlet.2026.218856_bib164","article-title":"Fibroblast activation protein and the tumour microenvironment: challenges and therapeutic opportunities","volume":"19\u20132025","author":"Lee","year":"2025","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.canlet.2026.218856_bib165","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35728","article-title":"A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers","volume":"131","author":"Ahmed","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib166","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-24-3918","article-title":"177Lu-LNC1004 radioligand therapy in patients with end-stage metastatic cancers: a single-center, single-arm, phase II study","volume":"31","author":"Fu","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib167","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.canlet.2026.218856_bib168","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1200\/JCO.2025.43.16_suppl.3028","article-title":"First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors","volume":"43","author":"Torres-Jim\u00e9nez","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib169","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1038\/s41416-024-02639-1","article-title":"Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity","volume":"130","author":"Akai","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125190","article-title":"FAP-targeting biomimetic nanosystem to restore the activated cancer-associated fibroblasts to quiescent state for breast cancer radiotherapy","volume":"670","author":"Gao","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.canlet.2026.218856_bib171","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40265-026-02305-1","article-title":"Retlirafusp alfa: first approval","volume":"86","author":"Keam","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2026.218856_bib172","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1083\/jcb.201609037","article-title":"Integrin-mediated mechanotransduction","volume":"215","author":"Sun","year":"2016","journal-title":"JCB (J. Cell Biol.)"},{"key":"10.1016\/j.canlet.2026.218856_bib173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.canlet.2026.218856_bib174","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1242\/jcs.039446","article-title":"Adhesion signaling \u2013 crosstalk between integrins, Src and rho","volume":"122","author":"Huveneers","year":"2009","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2026.218856_bib175","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1016\/j.yexcr.2007.07.002","article-title":"Activation of ROCK by RhoA is regulated by cell adhesion, shape, and cytoskeletal tension","volume":"313","author":"Bhadriraju","year":"2007","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.canlet.2026.218856_bib176","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074659","article-title":"Integrin-specific control of focal adhesion kinase and RhoA regulates membrane protrusion and invasion","volume":"8","author":"Costa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218856_bib177","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1152\/physrev.00005.2014","article-title":"The biology of YAP\/TAZ: hippo signaling and beyond","volume":"94","author":"Piccolo","year":"2014","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.canlet.2026.218856_bib178","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.yexcr.2015.10.034","article-title":"Role of YAP\/TAZ in cell-matrix adhesion-mediated signalling and mechanotransduction","volume":"343","author":"Dupont","year":"2016","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.canlet.2026.218856_bib179","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nrm1490","article-title":"Integrin signalling during tumour progression","volume":"5","author":"Guo","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib180","article-title":"Integrin signaling in tumor biology: mechanisms of intercellular crosstalk and emerging targeted therapies","volume":"13","author":"Li","year":"2025","journal-title":"PeerJ"},{"key":"10.1016\/j.canlet.2026.218856_bib181","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1083\/jcb.200204153","article-title":"The relationship between force and focal complex development","volume":"159","author":"Galbraith","year":"2002","journal-title":"JCB (J. Cell Biol.)"},{"key":"10.1016\/j.canlet.2026.218856_bib182","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.yexcr.2016.10.001","article-title":"Molecular mechanisms of mechanotransduction in integrin-mediated cell-matrix adhesion","volume":"349","author":"Li","year":"2016","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.canlet.2026.218856_bib183","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12442","article-title":"Substrate stiffness regulated migration and invasion ability of adenoid cystic carcinoma cells via RhoA\/ROCK pathway","volume":"51","author":"Zhao","year":"2018","journal-title":"Cell Prolif."},{"key":"10.1016\/j.canlet.2026.218856_bib184","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1186\/s12885-021-08982-3","article-title":"Inhibition of matrix stiffness relating integrin \u03b21 signaling pathway inhibits tumor growth in vitro and in hepatocellular cancer xenografts","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib185","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41388-025-03317-z","article-title":"ITGB1\/FERMT1 mechanoactivation enhances CD44 characteristic stemness in oral squamous cell carcinoma via ubiquitin-dependent CK1\u03b1 degradation","volume":"44","author":"Li","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218856_bib186","doi-asserted-by":"crossref","DOI":"10.1091\/mbc.E25-03-0106","article-title":"Inside\u2013out integrin activation is essential for early mammalian development","volume":"36","author":"Venkatesh","year":"2025","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.canlet.2026.218856_bib187","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/0955-0674(92)90099-X","article-title":"Inside-out integrin signalling","volume":"4","author":"Ginsberg","year":"1992","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2025.114629","article-title":"Metastatic breast cancer cells adapt to a soft environment with limited involvement of mechanotransduction","volume":"450","author":"Kumai","year":"2025","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.canlet.2026.218856_bib189","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax2770","article-title":"ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer","volume":"5","author":"Kuninty","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218856_bib190","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.apsb.2025.10.022","article-title":"Engineered cyclic peptide targeting ITGA5 disrupts tumor\u2013stroma interaction to overcome desmoplasia and resistance in pancreatic ductal adenocarcinoma","volume":"16","author":"Mardhian","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2026.218856_bib191","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0092-8674(00)80545-0","article-title":"A mechanism for regulating pulmonary inflammation and fibrosis: the integrin \u03b1v\u03b26 binds and activates latent TGF \u03b21","volume":"96","author":"Munger","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218856_bib192","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1172\/JCI45589","article-title":"Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin \u03b1v\u03b28\u2013mediated activation of TGF-\u03b2","volume":"121","author":"Kitamura","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218856_bib193","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.bbadis.2012.10.005","article-title":"Integrin-mediated regulation of TGF\u03b2 in fibrosis","volume":"1832","author":"Henderson","year":"2013","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.canlet.2026.218856_bib194","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1164\/rccm.200706-806OC","article-title":"Inhibition of integrin \u03b1v\u03b26, an activator of latent transforming growth Factor-\u03b2, prevents radiation-induced lung fibrosis","volume":"177","author":"Puthawala","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.canlet.2026.218856_bib195","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1186\/s12967-025-07119-5","article-title":"ITGB5-mediated biomechanical regulation in pancreatic ductal adenocarcinoma stroma impacts tumor progression and prognosis","volume":"23","author":"Yang","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108458","article-title":"Integrins in cancer: emerging mechanisms and therapeutic opportunities","volume":"247","author":"Liu","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2026.218856_bib197","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122591","article-title":"Integrin \u03b1v\u03b28\u2013expressing tumor cells evade host immunity by regulating TGF-\u03b2 activation in immune cells","volume":"3","author":"Takasaka","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218856_bib198","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.biomaterials.2018.05.056","article-title":"Integrin \u03b16 and EGFR signaling converge at mechanosensitive calpain 2","volume":"178","author":"Schwartz","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2026.218856_bib199","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/JCO.2024.42.16_suppl.8521","article-title":"Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: updated phase 1 results (SGNB6A-001)","volume":"42","author":"Peters","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib200","article-title":"Advances in clinical oncology research on 99mTc-3PRGD2 SPECT imaging","volume":"12","author":"Xiao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib201","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1200\/JCO.2025.43.16_suppl.8017","article-title":"Integrin \u03b1V\u03b23-targeted imaging for identification of lung cancer and mapping of lymph-node metastases: a prospective, multicenter, self-controlled phase 3 trial (TRIIL study)","volume":"43","author":"Zhu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib202","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/jcp.31001","article-title":"Regulation of PIEZO1 channels by lipids and the structural components of extracellular matrix\/cell cytoskeleton","volume":"238","author":"Vasileva","year":"2023","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.canlet.2026.218856_bib203","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.1038\/s41467-022-35034-6","article-title":"Membrane curvature governs the distribution of Piezo1 in live cells","volume":"13","author":"Yang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218856_bib204","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s42003-019-0514-3","article-title":"Myosin-II mediated traction forces evoke localized Piezo1-dependent Ca2+ flickers","volume":"2","author":"Ellefsen","year":"2019","journal-title":"Commun. Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib205","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aeb1271","article-title":"Compressive stress\u2013driven Piezo1 activation and Rho-ROCK mechanotransduction promote tumor progression via epigenetic mechanical memory","volume":"12","author":"Boyle","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218856_bib206","article-title":"The role of Piezo1 mechanotransduction in high-grade serous ovarian cancer: insights from an in vitro model of collective detachment","volume":"10","author":"Micek","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218856_bib207","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2024.119871","article-title":"PIEZO1 mediates matrix stiffness-induced tumor progression in kidney renal clear cell carcinoma by activating the Ca2+\/Calpain\/YAP pathway","volume":"1872","author":"Zhu","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.canlet.2026.218856_bib208","doi-asserted-by":"crossref","DOI":"10.1063\/5.0210134","article-title":"Three-dimensional matrix stiffness modulates mechanosensitive and phenotypic alterations in oral squamous cell carcinoma spheroids","volume":"8","author":"Sheth","year":"2024","journal-title":"APL Bioeng."},{"key":"10.1016\/j.canlet.2026.218856_bib209","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s12672-025-02456-9","article-title":"The increased matrix stiffness caused by LOXL2 activates Piezo1 channels to promote the migration and invasion of cervical cancer cells","volume":"16","author":"Liu","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib210","article-title":"Matrix stiffness drives squamous cell carcinoma progression via a Piezo1-mediated mechanotransduction feedback loop","author":"Jiang","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.canlet.2026.218856_bib211","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71059","article-title":"Piezo1\/ITGB1 synergizes with Ca2+\/YAP signaling to propel bladder carcinoma progression via a stiffness-dependent positive feedback loop","volume":"14","author":"Ma","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2026.218856_bib212","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41388-025-03611-w","article-title":"HOMER3 drives oral squamous cell carcinoma progression through TRPV6 calcium influx and TUBB3 microtubule stabilization","volume":"45","author":"Xu","year":"2026","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218856_bib213","article-title":"Mechanosensitive channel Piezo1 in calcium dynamics: structure, function, and emerging therapeutic strategies","volume":"12\u20132025","author":"Liu","year":"2025","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.canlet.2026.218856_bib214","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116502","article-title":"Piezo1 and its inhibitors: overview and perspectives","volume":"273","author":"Thien","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2026.218856_bib215","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1101\/gad.1903310","article-title":"The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation","volume":"24","author":"Lian","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2026.218856_bib216","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5483\/BMBRep.2018.51.3.015","article-title":"DNA binding partners of YAP\/TAZ","volume":"51","author":"Kim","year":"2018","journal-title":"BMB Rep."},{"key":"10.1016\/j.canlet.2026.218856_bib217","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1101\/gad.1664408","article-title":"TEAD mediates YAP-dependent gene induction and growth control","volume":"22","author":"Zhao","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2026.218856_bib218","doi-asserted-by":"crossref","first-page":"26743","DOI":"10.1074\/jbc.M111.233700","article-title":"The interaction between nesprins and sun proteins at the nuclear envelope is critical for force transmission between the nucleus and cytoskeleton","volume":"286","author":"Lombardi","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218856_bib219","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.cell.2017.10.008","article-title":"Force triggers YAP nuclear entry by regulating transport across nuclear pores","volume":"171","author":"Elosegui-Artola","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218856_bib220","doi-asserted-by":"crossref","DOI":"10.1242\/dev.201013","article-title":"Actomyosin-mediated cellular tension promotes Yap nuclear translocation and myocardial proliferation through \u03b15 integrin signaling","volume":"150","author":"Li","year":"2023","journal-title":"Development"},{"key":"10.1016\/j.canlet.2026.218856_bib221","article-title":"Matrix stiffness drives drop like nuclear deformation and lamin A\/C tension-dependent YAP nuclear localization","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218856_bib222","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41419-022-04729-5","article-title":"Lamin A and the LINC complex act as potential tumor suppressors in ewing sarcoma","volume":"13","author":"Chiarini","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218856_bib223","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1158\/0008-5472.CAN-17-0391","article-title":"Src inhibits the hippo tumor suppressor pathway through tyrosine phosphorylation of Lats1","volume":"77","author":"Si","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib224","doi-asserted-by":"crossref","first-page":"500","DOI":"10.7555\/JBR.39.20250198","article-title":"Overexpression of DDR1 contributes to gastric cancer progression by inhibiting the hippo pathway","volume":"39","author":"Han","year":"2025","journal-title":"J. Biomed. Res."},{"key":"10.1016\/j.canlet.2026.218856_bib225","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/s41418-023-01166-5","article-title":"Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via hippo signaling repression","volume":"30","author":"Xiong","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2026.218856_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2024.213936","article-title":"Matrix stiffening facilitates stemness of liver cancer stem cells by YAP activation and BMF inhibition","volume":"163","author":"Ma","year":"2024","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.canlet.2026.218856_bib227","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10375","article-title":"Pin1\/YAP pathway mediates matrix stiffness-induced epithelial\u2013mesenchymal transition driving cervical cancer metastasis via a Non-Hippo mechanism","volume":"8","author":"Yang","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib228","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1038\/s41591-025-04029-3","article-title":"YAP\/TEAD inhibitor VT3989 in solid tumors: a phase 1\/2 trial","volume":"31","author":"Yap","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib229","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18330","article-title":"YAP\/TAZ-TEAD signalling axis: a new therapeutic target in malignant pleural mesothelioma","volume":"28","author":"Papavassiliou","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib230","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","article-title":"Direct and selective pharmacological disruption of the YAP\u2013TEAD interface by IAG933 inhibits Hippo-dependent and RAS\u2013MAPK-altered cancers","volume":"5","author":"Chapeau","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib231","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao0475","article-title":"Targeting extracellular matrix stiffness to attenuate disease: from molecular mechanisms to clinical trials","volume":"10","author":"Lampi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib232","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.cell.2007.05.041","article-title":"Structural basis for the autoinhibition of focal adhesion kinase","volume":"129","author":"Lietha","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218856_bib233","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1128\/MCB.24.12.5353-5368.2004","article-title":"FERM domain interaction promotes FAK signaling","volume":"24","author":"Dunty","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib234","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nsb755","article-title":"The focal adhesion targeting (FAT) region of focal adhesion kinase is a four-helix bundle that binds paxillin","volume":"9","author":"Hayashi","year":"2002","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib235","article-title":"Conformational dynamics and multimodal interaction of paxillin with the focal adhesion targeting domain","volume":"11","author":"Bhattacharya","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218856_bib236","article-title":"Mechanochemical waves in focal adhesions during cell migration","volume":"11","author":"Fern\u00e1ndez-Yag\u00fce","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218856_bib237","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/biom10020179","article-title":"FAK structure and regulation by membrane interactions and force in focal adhesions","volume":"10","author":"Tapial Mart\u00ednez","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.canlet.2026.218856_bib238","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/s41467-021-22602-5","article-title":"Force-FAK signaling coupling at individual focal adhesions coordinates mechanosensing and microtissue repair","volume":"12","author":"Zhou","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218856_bib239","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.addr.2010.11.001","article-title":"Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis","volume":"63","author":"Zhao","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2026.218856_bib240","doi-asserted-by":"crossref","DOI":"10.31083\/j.fbl2911392","article-title":"Signal transduction mechanisms of focal adhesions: src and FAK-mediated cell response","volume":"29","author":"Katoh","year":"2024","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.canlet.2026.218856_bib241","article-title":"Diabetic hyperglycemia promotes primary tumor progression through glycation-induced tumor extracellular matrix stiffening","volume":"8","author":"Wang","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218856_bib242","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1038\/s41467-022-30105-0","article-title":"EZH2 engages TGF\u03b2 signaling to promote breast cancer bone metastasis via integrin \u03b21-FAK activation","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218856_bib243","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/s41467-025-57196-9","article-title":"Structure-based discovery of hydrocarbon-stapled paxillin peptides that block FAK scaffolding in cancer","volume":"16","author":"Reyes","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218856_bib244","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092059","article-title":"Altering FAK-paxillin interactions reduces adhesion, migration and invasion processes","volume":"9","author":"Deramaudt","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218856_bib245","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/2159-8290.CD-22-0192","article-title":"Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade","volume":"12","author":"Lander","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218856_bib246","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib247","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1038\/s41591-025-03763-y","article-title":"Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial","volume":"31","author":"Banerjee","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib248","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70210","article-title":"Preclinical evaluation of avutometinib and defactinib in high\u2010grade endometrioid endometrial cancer","volume":"13","author":"Hartwich","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2026.218856_bib249","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s40265-025-02215-8","article-title":"Avutometinib and defactinib: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2026.218856_bib250","article-title":"Focal adhesion kinase (FAK) inhibition synergizes with KRAS G12C inhibitors in treating cancer through the regulation of the FAK\u2013YAP signaling","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2026.218856_bib251","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2026.44.2_suppl.740","article-title":"A phase II study of stereotactic body radiotherapy and focal adhesion kinase inhibitor in advanced pancreatic adenocarcinoma","volume":"44","author":"Kim","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218856_bib252","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/ijc.29522","article-title":"Targeting FAK scaffold functions inhibits human renal cell carcinoma growth","volume":"137","author":"B\u00e9raud","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib253","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004021","article-title":"Disrupting the scaffold to improve focal adhesion kinase\u2013targeted cancer therapeutics","volume":"6","author":"Cance","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.canlet.2026.218856_bib254","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41556-025-01697-8","article-title":"Durotaxis is a driver and potential therapeutic target in lung fibrosis and metastatic pancreatic cancer","volume":"27","author":"Al-Hilal","year":"2025","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib255","article-title":"Establishing selectivity of FAK-paxillin PPI inhibitor using pulldown proteomics and a focal adhesion protein selectivity panel","volume":"45","author":"O'Brien","year":"2026","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.canlet.2026.218856_bib256","doi-asserted-by":"crossref","first-page":"17019","DOI":"10.1021\/jacs.8b08008","article-title":"Addressing kinase-independent functions of fak via PROTAC-Mediated degradation","volume":"140","author":"Cromm","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.canlet.2026.218856_bib257","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/0008-5472.CAN-25-4947","article-title":"Breaking the mechanical compass: disrupting durotaxis to halt fibrosis and metastasis","volume":"86","author":"Chitty","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib258","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1152\/physrev.00045.2020","article-title":"Rho GTPase signaling in cancer progression and dissemination","volume":"102","author":"Crosas-Molist","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.canlet.2026.218856_bib259","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ceb.2009.05.006","article-title":"Focal adhesion kinase: switching between GAPs and GEFs in the regulation of cell motility","volume":"21","author":"Tomar","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib260","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13046-021-02091-6","article-title":"TAGLN mediated stiffness-regulated ovarian cancer progression via RhoA\/ROCK pathway","volume":"40","author":"Wei","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib261","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.cell.2018.12.038","article-title":"Regional activation of myosin II in cancer cells drives tumor progression via a secretory cross-talk with the immune microenvironment","volume":"176","author":"Georgouli","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218856_bib262","first-page":"5","article-title":"Rho, ROCK and actomyosin contractility in metastasis as drug targets","author":"Rodriguez-Hernandez","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.canlet.2026.218856_bib263","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.actbio.2019.02.015","article-title":"ROCK isoforms differentially modulate cancer cell motility by mechanosensing the substrate stiffness","volume":"88","author":"Peng","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.canlet.2026.218856_bib264","first-page":"7","article-title":"ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth","volume":"9","author":"Rath","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib265","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ajpath.2013.05.014","article-title":"Mechanotransduction pathways promoting tumor progression are activated in invasive human squamous cell carcinoma","volume":"183","author":"Ibbetson","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2026.218856_bib266","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8504","article-title":"Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis","volume":"9","author":"Vennin","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib267","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4082","article-title":"Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression","volume":"22","author":"Laklai","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib268","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183871","article-title":"Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer","volume":"12","author":"Whatcott","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218856_bib269","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41419-025-07697-8","article-title":"Extracellular matrix stiffness in endometrial cancer: driving progression and modulating treatment sensitivity via the ROCK1\/YAP1 axis","volume":"16","author":"Sun","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218856_bib270","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1091\/mbc.e06-08-0684","article-title":"Fibronectin matrix assembly requires distinct contributions from Rho kinases I and-II","volume":"18","author":"Yoneda","year":"2007","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.canlet.2026.218856_bib271","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1529\/biophysj.108.133116","article-title":"Contact guidance mediated three-dimensional cell migration is regulated by Rho\/ROCK-Dependent matrix reorganization","volume":"95","author":"Provenzano","year":"2008","journal-title":"Biophys. J."},{"key":"10.1016\/j.canlet.2026.218856_bib272","doi-asserted-by":"crossref","first-page":"C436","DOI":"10.1152\/ajpcell.00225.2014","article-title":"Comparative mechanisms of cancer cell migration through 3D matrix and physiological microtracks","volume":"308","author":"Carey","year":"2014","journal-title":"Am. J. Physiol.: Cell Physiol."},{"key":"10.1016\/j.canlet.2026.218856_bib273","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/ncb1658","article-title":"Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells","volume":"9","author":"Gaggioli","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib274","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.bpj.2019.09.024","article-title":"Extent of cell confinement in microtracks affects speed and results in differential matrix strains","volume":"117","author":"Mosier","year":"2019","journal-title":"Biophys. J."},{"key":"10.1016\/j.canlet.2026.218856_bib275","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1038\/s41467-019-12155-z","article-title":"Energetic costs regulated by cell mechanics and confinement are predictive of migration path during decision-making","volume":"10","author":"Zanotelli","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218856_bib276","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.3390\/jcm14061856","article-title":"Advances in extracellular matrix-associated diagnostics and therapeutics","volume":"14","author":"Karsdal","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib277","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41419-017-0251-9","article-title":"Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2\/ABCG2","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218856_bib278","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s13046-019-1385-7","article-title":"RhoC regulates radioresistance via crosstalk of ROCK2 with the DNA repair machinery in cervical cancer","volume":"38","author":"Pranatharthi","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib279","doi-asserted-by":"crossref","first-page":"247","DOI":"10.17219\/acem\/166673","article-title":"miR-214-5p increases the radiosensitivity of cervical cancer by targeting ROCK1 expression","volume":"33","author":"Zhang","year":"2024","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218856_bib280","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41397-020-0153-6","article-title":"Rational design of small molecule RHOA inhibitors for gastric cancer","volume":"20","author":"Kim","year":"2020","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.canlet.2026.218856_bib281","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.chembiol.2025.08.004","article-title":"A covalent inhibitor targeting Cys16 on RhoA in colorectal cancer","volume":"32","author":"Koo","year":"2025","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.canlet.2026.218856_bib282","article-title":"Covalent inhibitors allosterically block the activation of rho family proteins and suppress cancer cell invasion","volume":"7","author":"Sun","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2026.218856_bib283","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.trecan.2022.12.001","article-title":"Preclinical to clinical utility of ROCK inhibitors in cancer","volume":"9","author":"Barcelo","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2026.218856_bib284","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1158\/1078-0432.CCR-20-0700","article-title":"First-in-Human study of AT13148, a dual ROCK-AKT inhibitor in patients with solid tumors","volume":"26","author":"McLeod","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218856_bib285","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nnano.2012.167","article-title":"The nanomechanical signature of breast cancer","volume":"7","author":"Plodinec","year":"2012","journal-title":"Nat. Nanotechnol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:26:46Z","timestamp":1792823206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526006208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":285,"alternative-id":["S0304383526006208"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218856","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting extracellular matrix mechanobiology to suppress solid tumor progression","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218856"}}